10x Genomics, Inc. announced a collaboration with the Cancer Research Institute (CRI) to advance the frontiers of immuno-oncology through high-resolution molecular data and AI. The multi-phase project will combine 10x's Chromium single cell and Xenium spatial platforms with advanced AI to build one of the world's most comprehensive translational and preclinical immuno-oncology datasets, spanning more than 20,000 samples, to reveal how the immune system recognizes and responds to cancer and to inform smarter treatment and prevention strategies for the future. Together, they intend to generate approximately 3,000 samples and analyze them using 10x's Chromium and Xenium platforms, which were selected for this project because they enable generation of large-scale, high-quality datasets with the resolution, consistency and throughput required for AI-driven immuno-oncology analyses.
These pilot datasets will be used to benchmark early AI models and determine which cellular and microenvironmental features are most predictive in preclinical settings. Following the pilot, the full project phase will expand to a broader network of laboratories, dramatically increasing the scale of sample generation across sites. To support this scale, CRI will incorporate 10x's Chromium Flex single cell assay, purpose-built for ultra high-throughput studies, to profile more than 500 million cells.
CRI will use this integrated dataset to uncover mechanisms of immune response and resistance, refine and improve existing immuno-oncology treatments, identify opportunities for new therapeutic strategies and lay the groundwork for future vaccine discovery. Together, this work will deepen understanding of how to more effectively harness the immune system to prevent and treat cancer. This initiative builds on CRI's long-standing approach of funding, connecting and accelerating immunotherapy discovery, from foundational biology to translational science and clinical application.
It also further extends CRI's legacy of leadership in the field, including support for the studies that led to the HPV vaccine Gardasil®?, one of the first cancer-preventive vaccines, and represents the next evolution of CRI's mission of a world immune to cancer by fueling the discovery and development of powerful immunotherapies for all cancers.
